Trials / Completed
CompletedNCT06099613
Study to Safety, Tolerability and Immunogenicity of EG-COVII in Healthy Adult
A Phase I/IIa Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVII in Healthy Adult Volunteers
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- EyeGene Inc. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase I/IIa Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVII in Healthy Adult Volunteers
Detailed description
Subjects will undergo a Screening period beginning up to 2 weeks prior to enrollment, the vaccinations will be administered on week 0 and week 3, pre- and post-dose assessment, follow-up visits, and an end of study (EOS) or early termination (ET) visit (as applicable).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | EG-COVII | EG-COVII is a bivalent vaccine to prevent SARS-CoV-2 infection against wild type and Omicron variants |
Timeline
- Start date
- 2023-11-30
- Primary completion
- 2024-11-01
- Completion
- 2025-02-28
- First posted
- 2023-10-25
- Last updated
- 2025-03-07
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT06099613. Inclusion in this directory is not an endorsement.